newsfilter
← Earnings
Earnings Releases·

Upstream Bio — Third Quarter 2026 Earnings Summary

Upstream Bio, Inc. reported a net loss of $41.2 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its verekitug programs. The company holds $207.4 million in cash and short-term investments, which is projected to fund operations through 2027. Upstream Bio plans to initiate Phase 3 clinical trials for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps during the first quarter of 2027. Additionally, ongoing Phase 2 trials for verekitug in COPD and severe asthma are expected to yield data in the second half of 2027.

Company
UPSTREAM BIO INC
Sector
Healthcare
Industry
Biotechnology